1 min read

Opportunities for Treg cell therapy for the treatment of human disease

On this page

Share

Regulatory T (Treg) cells are essential for maintaining peripheral tolerance, preventing autoimmunity, and limiting chronic inflammatory diseases. This small CD4+ T cell population can develop in the thymus and in the peripheral tissues of the immune system through the expression of an epigenetically stabilized transcription factor, FOXP3. Treg cells mediate their tolerogenic effects using multiple modes of action, including the production of inhibitory cytokines, cytokine starvation of T effector (e.g., IL-2), Teff suppression by metabolic disruption, and modulation of antigen-presenting cell maturation or function.

Related Articles

Explore posts connected to this topic

Tr1X, Inc. to highlight Miltenyi Biotec CDMO capabilities for scalable allogeneic cell therapy manufacturing at the 11th Annual CAR-TCR Summit

San Diego, CA, and Bergisch Gladbach, Germany – September 15, 2026 – Tr1X, Inc. and Miltenyi Biotec today announced that...

CIRM approves more than $60 million to support clinical and preclinical development awards

South San Francisco, CA, June 25, 2026 – The California

Tr1X to Present New Clinical and Preclinical Data on Engineered Tr1 Treg Cell Therapies at ASGCT 2026

SAN DIEGO–(BUSINESS WIRE)–Tr1X, Inc., a clinical-stage autoimmune and inflammatory disease